Price T Rowe Associates Inc. MD Takes $11.88 Million Position in Septerna, Inc. (NASDAQ:SEPN)

Price T Rowe Associates Inc. MD bought a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 518,588 shares of the company's stock, valued at approximately $11,877,000. Price T Rowe Associates Inc. MD owned 1.17% of Septerna as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC bought a new stake in Septerna during the fourth quarter valued at about $25,000. New York State Common Retirement Fund bought a new position in shares of Septerna during the 4th quarter valued at approximately $32,000. Legal & General Group Plc purchased a new stake in Septerna in the 4th quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in Septerna during the 4th quarter worth approximately $45,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of Septerna in the fourth quarter worth approximately $61,000.

Insider Buying and Selling at Septerna

In other news, CFO Gil M. Labrucherie bought 10,500 shares of the stock in a transaction on Wednesday, February 19th. The stock was acquired at an average cost of $5.51 per share, for a total transaction of $57,855.00. Following the acquisition, the chief financial officer now owns 10,500 shares of the company's stock, valued at $57,855. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan Ezekowitz purchased 41,355 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were purchased at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the purchase, the director now owns 104,101 shares of the company's stock, valued at approximately $624,606. This trade represents a 65.91 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 74,346 shares of company stock valued at $439,670 in the last three months.

Septerna Stock Down 9.9 %

SEPN stock traded down $0.71 during mid-day trading on Tuesday, reaching $6.45. 223,178 shares of the stock traded hands, compared to its average volume of 416,596. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99. The company has a 50-day simple moving average of $6.12.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, equities research analysts expect that Septerna, Inc. will post -7.11 EPS for the current year.

Analyst Upgrades and Downgrades

SEPN has been the topic of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, March 28th. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.